ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2012
[Correlation of KLF4 and SPARC expression with the clinical characteristics of non-small cell lung cancer].
Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 9 citations in OpenAlex.
- SPARC: a potential target for functional nanomaterials and drugs.Frontiers in molecular biosciences · 2023Review
- Prognostic significance of SPARC expression in non-small cell lung cancer: A meta-analysis and bioinformatics analysis.Oncology letters · 2022Article
- Role of Krüppel-like factor 4 and heat shock protein 27 in cancer of the larynx.Molecular and clinical oncology · 2017Article
- Article
- Krüppel-like factor 4: A new potential biomarker of lung cancer.Molecular and clinical oncology · 2016Article
- High cytoplasmic expression of Krüppel-like factor 4 is an independent prognostic factor of better survival in hepatocellular carcinoma.International journal of molecular sciences · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveIt has been proven that the development and biological behavior of lung carcinoma is affected by a number of signaling pathway elements. The expression levels of Krüppel-like factor 4 (KLF4) and secreted protein acidic and rich in cysteine (SPARC) were correlated with tumorigenesis and prognosis. This study aims to investigate KLF4 and SPARC expression and their correlation with the clinical characteristics of non-small cell lung cancer (NSCLC).
methodsKLF4 and SPARC expression was examined immunohistochemically in NSCLC and normal lung tissues from 89 patients.
resultsSPARC expression was increased in the tumor specimens compared with the control tissue (70.8% vs 7.9%, P<0.05), whereas KLF4 protein was reduced compared with that in the control tissue (42.7% vs 88.8%, P<0.05). KLF4 expression was significantly correlated with lymph node metastasis and clinical stage (P<0.05). KLF4 expression in NSCLC decreased with the increasing clinical stage. The positive rate of SPARC expression in NSCLC with lymph node metastasis was significantly higher than that without lymph node metastasis (81.3% vs 58.5%, P<0.05). Lung carcinomas in stages I and II disease had significantly lower rates of positive SPARC expression than that in stages III and IV diseases (P<0.05). Both were not related to age, sex, and tumor size (P>0.05). KLF4 expression was negatively correlated with SPARC expression in NSCLC (r=-0.245, P<0.05).
conclusionsThe SPARC overexpression may play an important role in the initiation and development of NSCLC, whereas KLF4 inhibits this process. These proteins may be used as marker for evaluating the biological characteristics and clinical stages of NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.